{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-25-000104","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.654191+00:00","generated_at":"2026-05-17T02:08:15.859752+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin Q3 net loss $31M vs income $106M YoY; revenue +4% to $776M; guidance raised","bullets":["GAAP net loss of $31M (diluted EPS -$0.16) vs income $106M ($0.55) in Q3 2024, due to $221M IPR&D charge from Inozyme acquisition.","Non-GAAP income fell to $22M ($0.12 EPS) from $178M ($0.91), reflecting the Inozyme charge and SG&A investments.","Total revenue $776M (+4% YoY); VOXZOGO $218M (+15%), PALYNZIQ $109M (+20%), but ALDURAZYME -24% and NAGLAZYME -8%.","Full-year 2025 total revenue guidance raised at midpoint; VOXZOGO outlook reaffirmed at $900M-$935M.","Company pursuing options to divest ROCTAVIAN (hemophilia A gene therapy), including out-licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-25-000104","json":"https://secwatch.observer/filing/0001048477-25-000104.json","markdown":"https://secwatch.observer/filing/0001048477-25-000104.md","text":"https://secwatch.observer/filing/0001048477-25-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/0001048477-25-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/bmrn-20251027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:08:15.859752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}